The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb has opened a $160M radiopharma facility in Indianapolis, scaling up production since acquiring RayzeBio ...

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem.

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem. The deal is worth $350 ...

Indianapolis plans to send street outreach teams to homeless camps across the city and move around 350 people into stable housing.

After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop ...

RayzeBio, a radiopharmaceutical therapeutics developer, and members of its board of directors were slapped with a securities lawsuit on Feb. 5 in Delaware District Court over the company's ...

Bristol Myers Squibb's $4.1 billion bid for RayzeBio was enough to beat out two other companies that also put down offers.

RayzeBio is completing construction of a state-of-the-art in-house manufacturing facility in Indianapolis, IN, and GMP drug production is expected to begin in the first half of 2024.

With the buyout deal, Bristol Myers will have access to RayzeBio's drug production facility located in Indianapolis, Indiana. It was agreed that the former would pay $62.50 in cash for every share ...